Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- R. Herbst, Jean-Charles Soria, +19 authors F. S. Hodi
- Biology, Medicine
- Nature
- 27 November 2014
The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish… Expand
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- M. Chao, Ash A. Alizadeh, +17 authors R. Majeti
- Biology, Medicine
- Cell
- 3 September 2010
Monoclonal antibodies are standard therapeutics for several cancers including the anti-CD20 antibody rituximab for B cell non-Hodgkin lymphoma (NHL). Rituximab and other antibodies are not curative… Expand
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- Idit Sagiv-Barfi, H. Kohrt, D. Czerwinski, P. P. Ng, B. Chang, R. Levy
- Biology, Medicine
- Proceedings of the National Academy of Sciences
- 17 February 2015
Significance Antibodies that block the negative signals between PD1-Ligand on tumor cells and PD-1 on T cells are effective therapies against several types of cancer. Ibrutinib, a covalent inhibitor… Expand
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
- A. Marabelle, H. Kohrt, +13 authors R. Levy
- Medicine
- The Journal of clinical investigation
- 3 June 2013
Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and… Expand
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
- A. Filatenkov, J. Baker, +11 authors S. Strober
- Medicine
- Clinical Cancer Research
- 13 April 2015
Purpose: The goals of the study were to elucidate the immune mechanisms that contribute to desirable complete remissions of murine colon tumors treated with single radiation dose of 30 Gy. This dose… Expand
New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients
- H. Kohrt, R. Olshen, +14 authors S. Jeffrey
- Medicine
- BMC Cancer
- 4 March 2008
BackgroundCurrent practice is to perform a completion axillary lymph node dissection (ALND) for breast cancer patients with tumor-involved sentinel lymph nodes (SLNs), although fewer than half will… Expand
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
Antibody-dependent cell-mediated cytotoxicity (ADCC), which is largely mediated by natural killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20… Expand
Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer
Background While lymph node metastasis is among the strongest predictors of disease-free and overall survival for patients with breast cancer, the immunological nature of tumor-draining lymph nodes… Expand
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.
Natural killer (NK) cells are potent anti-viral and antitumor "first responders" endowed with natural cytotoxicity and cytokine production capabilities. To date, attempts to translate these promising… Expand
The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses
- R. Pachynski, B. Zabel, +10 authors E. Butcher
- Medicine, Biology
- The Journal of experimental medicine
- 30 July 2012
Chemerin recruits NK cells to suppress melanoma growth.